Diehl’s Own CM
Cetyl myristoleate, also known as CM, is the cetyl ester of the fatty acid myristoleic acid (cis-9- tetradecenoic acid). It occurs in nature in sperm whales, in mice, and in the oil glands of male beavers. During the time he was a researcher at the National Institutes of Health (but in his home lab), Harry Diehl isolated cetyl myristoleate from the Swiss Albino mouse while looking for a treatment for arthritis. He received two U.S. Patents on cetyl myristoleate:
U.S. Patent # 4049824: Cetyl myristoleate, September 20, 1977;
U.S. Patent # 5569676: Method for the treatment of osteoarthritis, October 29, 1996.
Diehl’s Own® CM is made by reacting fatty acids, including myristoleic acid derived from beef tallow with cetyl alcohol.
Diehl’s Own® CM oil 40% is standardized to 40% cetyl myristoleate. (It also contains approximately 37% cetyl oleate,10% cetyl myristate, 6% cetyl linoleate and 3% cetyl palmitate, plus small amounts of other fatty acids esters).
Diehl’s Own® CM powder is standardized to 20% CM.
Benefits
• Cetyl myristoleate acts as a “surfactant” which lubricates the joints and connective tissues*
• Cetyl myristoleate regulates prostaglandin and leukotriene production*
• Cetyl myristoleate is an immuno-modulator*
Why Choose Us?
• Highest quality
• Priced to compete
• Available in both bulk liquid and powder
• Patented
GCI NUTRIENTS
GCI Nutrients is both a worldwide distributor of high quality commodity nutriceutical ingredients and raw materials and a developer of special products.
Designed to exceed competitor’s raw materials on key parameters, GCI’s branded ingredients allow a finished product manufacturer to enter a product category with a competitive edge.
GCI Nutrients in the U.S. serves the functional foods and beverages, sports, animal/pets, cosmeceutical and nutriceutical industries. There is an extensive array of products to meet your needs – hundreds of ingredients from quality commodities to unique proprietary products. These ingredients come in a selection of product forms –bulk powders, liquids, tablets, and soft gels.
Our unique network allows you to obtain difficult-to-find ingredients quickly. Also, our contract buying with select vendors establishes price stabilization and product consistency.
Studies
In 1997, Dr. H. Siemandi conducted a double blind study of Cetyl Myristoleate under the auspices of the Joint European Hospital Studies Program. There were 431 patients in the study, 106 who received cetyl myristoleate, 99 who received cetyl myristoleate, and glucosamine, sea cucumber, and hydrolyzed cartilage and 226 who received a placebo. Clinical assessment included radiological test and other studies. Results were 63% improvement for the cetyl myristoleate group, 87% for the cetyl myristoleate plus glucosamine group and 15% for the placebo group.
In August of 2002, a double blind study was published in the Journal or Rheumatology. The study included sixty-four patients with chronic knee OA. Half of the patients received cetyl myristoleate and half a placebo. Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI). The conclusion was that the CM group saw significant improvement, while the placebo group saw little to none. They state that CM “may be an alternative to the use of nonsteroidal anti-inflammatory drugs for the treatment of OA”.
In October of 2001, Advanced Medical Systems & Design, Ltd. completed a study involving Cetyl Myristoleate. It was not a double blind study, but the study included 1814 arthritis patients. The results showed that over 87% of the subjects had greater than 50% recovery and over 65% of those showed from 75% – 100% recovery following a sixteen day regimen.